Compare Stocks: SXTP, QNRX, FNCH, and KPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPRX Kiora Pharmaceuticals	$2.55 -1.5%	$2.56	$1.76 ▼ $3.01	$11.46M	-0.38	18,071 shs	41,172 shs
QNRX Quoin Pharmaceuticals	$5.09 -15.9%	$4.55	$3.25 ▼ $41.80	$12.15M	1.5	15,790 shs	64,689 shs
SXTP 60 Degrees Pharmaceuticals	$1.20 +1.3%	$1.47	$1.05 ▼ $8.62	$3.14M	2.54	110,563 shs	150,822 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-7.59%	-39.92%
KPRX Kiora Pharmaceuticals	-1.89%	+1.17%	+4.44%	+3.60%	+4.02%
QNRX Quoin Pharmaceuticals	+2.72%	+32.39%	+39.08%	+4.49%	-17.01%
SXTP 60 Degrees Pharmaceuticals	+4.42%	+2.61%	-19.18%	-15.11%	-78.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
KPRX Kiora Pharmaceuticals	$2.55 -1.5%	$2.56	$1.76 ▼ $3.01	$11.46M	-0.38	18,071 shs	41,172 shs
QNRX Quoin Pharmaceuticals	$5.09 -15.9%	$4.55	$3.25 ▼ $41.80	$12.15M	1.5	15,790 shs	64,689 shs
SXTP 60 Degrees Pharmaceuticals	$1.20 +1.3%	$1.47	$1.05 ▼ $8.62	$3.14M	2.54	110,563 shs	150,822 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-7.59%	-39.92%
KPRX Kiora Pharmaceuticals	-1.89%	+1.17%	+4.44%	+3.60%	+4.02%
QNRX Quoin Pharmaceuticals	+2.72%	+32.39%	+39.08%	+4.49%	-17.01%
SXTP 60 Degrees Pharmaceuticals	+4.42%	+2.61%	-19.18%	-15.11%	-78.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	2.00	Hold	$10.00	292.16% Upside
QNRX Quoin Pharmaceuticals	2.00	Hold	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.00	Hold	$13.85	1,059.00% Upside

Current Analyst Ratings Breakdown

Latest SXTP, QNRX, FNCH, and KPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	QNRX Quoin Pharmaceuticals	ThinkEquity Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/11/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.20 ➝ $3.70
5/20/2026	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
KPRX Kiora Pharmaceuticals	$16.02M	0.70	N/A	N/A	$3.81 per share	0.67
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A
SXTP 60 Degrees Pharmaceuticals	$1.41M	2.25	N/A	N/A	($5.85) per share	-0.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	N/A
QNRX Quoin Pharmaceuticals	-$15.81M	-$29.56	N/A	N/A	N/A	N/A	-489.85%	-221.29%	8/14/2026 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$7.36M	-$8.92	N/A	N/A	N/A	-574.91%	N/A	-131.48%	N/A

Latest SXTP, QNRX, FNCH, and KPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.83	-$1.90	-$0.07	-$1.90	N/A	N/A
8/14/2026	Q2 2026	SXTP 60 Degrees Pharmaceuticals	-$0.74	-$0.90	-$0.16	-$0.90	$0.19 million	$0.21 million
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A
5/15/2026	Q1 2026	SXTP 60 Degrees Pharmaceuticals	-$0.76	-$1.28	-$0.52	-$1.28	$0.44 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FNCH Finch Therapeutics Group	N/A	3.87	3.87
KPRX Kiora Pharmaceuticals	N/A	8.97	6.68
QNRX Quoin Pharmaceuticals	N/A	2.87	2.87
SXTP 60 Degrees Pharmaceuticals	N/A	3.34	2.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FNCH Finch Therapeutics Group	21.77%
KPRX Kiora Pharmaceuticals	76.97%
QNRX Quoin Pharmaceuticals	8.63%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
FNCH Finch Therapeutics Group	44.90%
KPRX Kiora Pharmaceuticals	0.52%
QNRX Quoin Pharmaceuticals	11.17%
SXTP 60 Degrees Pharmaceuticals	1.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
KPRX Kiora Pharmaceuticals	10	4.42 million	4.40 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	2.01 million	1.78 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	2.66 million	2.61 million	Not Optionable

SXTP, QNRX, FNCH, and KPRX Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

August 14 at 3:47 PM | globenewswire.com

60 Degrees Pharmaceuticals (SXTP) Projected to Post Earnings on Wednesday

August 11 at 3:10 AM | americanbankingnews.com

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

July 30, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

July 29, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

July 8, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis ...

July 1, 2026 | markets.businessinsider.com

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

July 1, 2026 | globenewswire.com

60 Degrees Pharmaceuticals (NASDAQ:SXTP) CEO Geoffrey Dow Acquires 7,350 Shares

June 16, 2026 | insidertrades.com

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

June 11, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

May 26, 2026 | globenewswire.com

HC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)

May 21, 2026 | msn.com

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

May 15, 2026 | globenewswire.com

60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38

April 30, 2026 | msn.com

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

April 15, 2026 | markets.businessinsider.com

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

April 3, 2026 | zacks.com

Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

April 2, 2026 | freep.comF

Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

April 2, 2026 | freep.comF

60 Degrees Pharmaceuticals Announces 2025 Annual Results

March 31, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

March 18, 2026 | globenewswire.com

60 Degrees Pharmaceuticals Updates Opinion for ATM Program

March 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, QNRX, FNCH, and KPRX Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 08/13/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.55 -0.04 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 0.00 (-0.20%)

As of 06:20 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Quoin Pharmaceuticals NASDAQ:QNRX

$5.09 -0.96 (-15.87%)

Closing price 04:00 PM Eastern

Extended Trading

$5.00 -0.09 (-1.75%)

As of 07:31 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.20 +0.02 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 -0.02 (-2.01%)

As of 07:59 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTP, QNRX, FNCH, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTP, QNRX, FNCH, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTP, QNRX, FNCH, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, QNRX, FNCH, and KPRX Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

Kiora Pharmaceuticals NASDAQ:KPRX

Quoin Pharmaceuticals NASDAQ:QNRX

60 Degrees Pharmaceuticals NASDAQ:SXTP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTP, QNRX, FNCH, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTP, QNRX, FNCH, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTP, QNRX, FNCH, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, QNRX, FNCH, and KPRX Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

Kiora Pharmaceuticals NASDAQ:KPRX

Quoin Pharmaceuticals NASDAQ:QNRX

60 Degrees Pharmaceuticals NASDAQ:SXTP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools